Engineered Probiotics as Tumor-Targeting Drug Factories
Recent advancements in biotechnology have led to the engineering of probiotic bacteria capable of infiltrating tumors and producing localized cancer therapies, demonstrating effectiveness in murine models.
Researchers have developed probiotic bacteria that are specifically engineered to locate and infiltrate tumor sites. This innovative approach enables the bacteria to act as localized drug production units.
The engineered probiotics are designed to synthesize cancer-fighting drugs directly at the tumor site, potentially increasing the efficacy of treatments while minimizing systemic side effects.
Initial studies conducted on mice have shown promising results, indicating that this targeted delivery system could enhance therapeutic outcomes in cancer treatment.